A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 3,201–3,300 of 3,965
Clinical approach to gastro-oesophageal reflux in idiopathic pulmonary fibrosis
Jones, R. (2016) · Cited by 1
Diagnostic difficulty in idiopathic pulmonary fibrosis
Kondoh, Y. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.03.012 · Cited by 1
Redox regulation in pulmonary fibrosis: towards therapeutic targets
Veith (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190524cv · Cited by 1
The semantics of language translation using mobile systems in South African healthcare
Makovhololo, P. (2018) · Cited by 3
Braun, C. M., Girtman, M. A., Jenson, P. E., Bourne, M. H., Chae, J., Kottom, T. J., & LIMPER, A. H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.178061 · Cited by 1
A proteomics workflow reveals predictive autoantigens in idiopathic pulmonary fibrosisPreprint
Leuschner, G., Mayr, C. H., Ansari, M., Seeliger, B., Frankenberger, M., Kneidinger, N., Hatz, R. A., Hilgendorff, A., Prasse, A., Behr, J., et al. (2021) · medRxiv · doi:10.1101/2021.02.17.21251826 · Cited by 1
Chronic Obstructive Pulmonary Disease Combined With Interstitial Lung DiseasePreprint
Choi, J. Y., Song, J. W., & Rhee, C. K. (2021) · Preprints.org · doi:10.20944/preprints202105.0083.v1 · Cited by 1
On the possibilities of colliding winds and accretion from stellar winds
Zamanov, R. K. (1993) · Observatory · Cited by 1
Ahangari, F., Becker, C., Foster, D. G., Chioccioli, M., Nelson, M., Beke, K. M., Wang, X., Readhead, B. P., Meador, C., Correll, K. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.04.474955 · Cited by 1
Pemafibrate Attenuates Pulmonary Fibrosis by Inhibiting Myofibroblast DifferentiationPreprint
Liu, Y., Chen, S., Yu, L., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4020792 · Cited by 1
Qi, X.-M., Wang, F., & Chen, G. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101521-1 · Cited by 1
Editorial: Mechanisms of Lung Fibrosis: Is Immunity Back in the Game?
Froidure, A., Antoniou, K. M., Bocchino, M., & Conte, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882979 · Cited by 1
“nintedanib and pirfenidone, has improved the clinical management of IPF patients slowing disease progression and preventing both AEs and hospitalization (5, 6).”
BackgroundYing, H., Fang, M., Hang, Q., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-125322/v1 · Cited by 1
Scleroderma Associated Interstitial Lung Disease
Castelino, F. V., & Steen, V. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00016-0 · Cited by 1
Morisset, J., & Ley, B. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00054-8 · Cited by 1
Forrest, I., & Bourke, A.-M. (2019) · Springer eBooks · doi:10.1007/978-3-030-18944-0_9 · Cited by 1
Dimmock, A. E. F., Chuang, C. H., Hwang, W., Lehmann, H. P., Danoff, S. K., & Bascom, R. (2022) · Research Square · doi:10.21203/rs.3.rs-2008034/v1 · Cited by 1
Zhao, R., Xie, B., Wang, X., Zhang, X., Ren, Y., Dai, H., & Wang, C. (2023) · Research Square · doi:10.21203/rs.3.rs-2787815/v1 · Cited by 1
Spatial Transcriptomic Characterization of Novel Pathologic Niches in IPFPreprint
Mayr, C. H., Santacruz, D., Jarosch, S., Lempp, C., Neubert, L., Rath, B., Kamp, J. C., Jonigk, D. D., Kühnel, M., Schlueter, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.13.571464 · Cited by 1
SGLT-2 Inhibitors as Novel Treatments of Multiple Organ FibrosisPreprint
Hu, J.-P., Hui, S., Teng, J., & Liang, L. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4680858 · Cited by 1
A protective role for B-1 cells and oxidation-specific epitope IgM in lung fibrosisPreprint
Sturek, J. M., Hannan, R. T., Upadhye, A., Otoupalova, E., Faron, E. T., Atya, A. A. E., Thomas, C., Johnson, V., Miller, A., Garmey, J. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.11.589137 · Cited by 1
Morisset, J. (2024) · CHEST Journal · doi:10.1016/j.chest.2024.03.041 · Cited by 1
Early pirfenidone treatment enhances lung function in idiopathic pulmonary fibrosis patients
Zhang, J. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i28.6247 · Cited by 1
Wang, R., Zhu, M., Lin, C., Gao, M., Liu, Y., & Cheng, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-4957398/v1 · Cited by 1
The role of GPR87 in Pulmonary FibrosisPreprint
Khoury, J., Ahangari, F., Adams, T. S., Justet, A., Manning, E. P., McDonough, J. E., Bärnthaler, T., Anderson, S., Nikola, F., Beermann, M. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.10.617569 · Cited by 1
Elastokines are Associated with a Poor Prognosis in Idiopathic Pulmonary FibrosisPreprint
Nagel, D. J., Okutani, T., Lopa, S., et al. (2025) · medRxiv · doi:10.1101/2025.06.06.25327886 · Cited by 1
Zhang, X., Liu, X., Qiao, Y., Rabata, A., Liu, N., Yao, C., Parimon, T., Chen, D., Chen, P., Stripp, B. R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.30.662456 · Cited by 1
Self-citationOtoupalova, E., Hannan, R. T., Raichura, P., Batrash, N., Dell, P., Rodrigues‐Jesus, M. J., Zunder, E. R., Wilson, J. M., Woodfolk, J. A., Taylor, J. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.11.28.691061 · Cited by 1
Therapie der idiopathischen Lungenfibrose
Schreiber, J. (2014) · Der Pneumologe · doi:10.1007/s10405-014-0819-3
Transbronchial cryobiopsy in diffuse parenchymal lung disease
Ussavarungsi, K., Patel, N. M., & Lee, A. S. (2015) · DOAJ (DOAJ: Directory of Open Access Journals)
Fibrosis pulmonar idiopática. Con el blanco en la mira
Otaola, M. (2014) · Redalyc (Universidad Autónoma del Estado de México)
Idiopathische Pulmonale Fibrose – ein Update
Errhalt, P. (2015) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Role of Progenitors in Pulmonary Fibrosis and Asthma
Banerjee, E. R. (2014) · Springer eBooks · doi:10.1007/978-81-322-2053-4_8
Vij, R., Denton, C. P., & Noth, I. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0751ed
Update on New Treatments for Idiopathic Pulmonary Fibrosis
DeGrado, J. R., & Gilmore, J. F. (2015) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-015-0076-8
Management of Scleroderma-Associated Pulmonary Involvement
Dobrota, R., Distler, O., Wells, A. U., & Humbert, M. J. C. (2015) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-014-0011-2
Idiopathische pulmonale Fibrose
Markart, P., Wygrecka, M., & Günther, A. (2015) · Pneumo News · doi:10.1007/s15033-014-0003-9
Ancochea, J., Pérez, T. A., Gutiérrez, M. D. V. S., & Valenzuela, C. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70847-9
Enfermedades pulmonares intersticiales difusas. Neumoconiosis. Neumonitis por hipersensibilidad
Pérez, T. A., Valenzuela, C., Moreno, R. M. G., et al. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70846-7
Kärperliches Training sollte zur Therapie gehären
Schultz, K. (2015) · Pneumo News · doi:10.1007/s15033-015-0092-0
An Efficient Inter-Coding Algorithm For H.264
Aslam, L., & Khan, N. A. (2007) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.40460
Hope for Disease-Modifying Treatment of Systemic Sclerosis/Scleroderma
Michel, M. C. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213520comm
Treatment of lymphangioleiomyomatosis and Camões
Rufino, R. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000400001
Tratamiento de la fibrosis pulmonar idiopática: de la teoría a la vida real
Nieto, A., & Valenzuela, C. (2015) · Monografías de Archivos de Bronconeumología
“The Long and Winding Road” seeking specific drugs for idiopathic pulmonary fibrosis
Munakata, M. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.12.001
Predictive factors for the effect of pirfenidone in idiopathic pulmonary fibrosis.
Ichimura, Y., Tsushima, K., Matsumura, T., et al. (2017) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v34i4.5630
Traitement médical de la fibrose pulmonaire idiopathique : de nouvelles perspectives
Bouvry, D., & Jouneau, S. (2014) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(14)70619-6
Fibrose pulmonaire idiopathique : une nouvelle ère, de nouveaux défis
Cottin, V. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.07.009
Idiopathische Lungenfibrose wird erstmals behandelbar
Einecke, D. (2015) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-015-2632-2
3) Pulmonary Fibrosis and Its Management
Azuma, A. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.105b
TGF-β-signaling in the regulation of vascular function and its impairment
Fukuhara, T., & Watabe, T. (2014) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.25.609
María Teresa Parada, C., Joel Melo, T., L, C. S., David Lazo, P., S, V. L., R, E. V., Clavero, J. M., C, M. L., Cristina Herzog, O., Lorena Calabrán, R., et al. (2015) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482015000400002 · Cited by 1
Neue Empfehlungen bei idiopathischer Lungenfibrose
Markart, P., & Gesierich, W. (2015) · Pneumo News · doi:10.1007/s15033-015-0214-8
Do New Drugs Meet the Expectations in the Treatment of Idiopathic Pulmonary Fibrosis?
Okutan, O., & Ayten, Ö. (2016) · Eurasian Journal of Pulmonology · doi:10.5152/ejp.2016.55376
Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension
Huston, J., Hatton, N. D., & Ryan, J. J. (2015) · Springer eBooks · doi:10.1007/978-3-319-23594-3_3
Pirfenidone in Lung Interstitial Diseases: Indications and How to Evaluate its Effects
Cuerpo, S., Hernández‐González, F., Xaubet, A., et al. (2016) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000153
Directed Differentiation of Human Pluripotent Stem Cells into Lung and Airway Epithelial Cells
Snoeck, H. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-3-319-21082-7_16
3e Journée française de la fibrose pulmonaire idiopathique. 19 septembre 2014
Cottin, V., Crestani, B., Danel, C. J., Debray, M., Nunès, H., Poletti, V. E., Prévost, G., Vergnon, J.-M., Wallaert, B., & Cordier, J. F. (2015) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2015.06.002
Maher, T. M., & Spagnolo, P. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006615 · Cited by 1
ADVANCES IN THERAPIES FOR INTERSTITIAL LUNG DISEASES
Ferrara, G., & Sköld, M. C. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814656337_0012
Grundlagen der medikamentösen Therapie
Drakopanagiotakis, F., & Günther, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48419-7_5
Key ongoing issues in trial design
Jones, M. G., & Richeldi, L. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006515
Diffuse Parenchymal Lung Diseases of Unknown Etiology
Weinberger, S. E., Cockrill, B. A., & Mandel, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-52371-4.00014-3
Chisholm, A., Eid, N. S., Navarrete, B. A., et al. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.07.16
Symptom management: dyspnoea and cough
Wuyts, W. A. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006215
Syn, W., & Diehl, A. M. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch8
Potential Mechanistic Links Between Aging and IPF
Pan, H., Gulati, M., & Herzog, E. L. (2015) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814635011_0016
A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?
Launay, D. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.160887
Death Receptors 4 and 5 and Idiopathic Pulmonary Fibrosis
Miller, S. (2016) · University of Minnesota Digital Conservancy (University of Minnesota)
Nintedanib for idiopathic pulmonary fibrosis: A n A sian perspective
Chambers, D. C. (2016) · Respirology · doi:10.1111/resp.12903
Vuga, L. J. (2016) · D-Scholarship@Pitt (University of Pittsburgh)
Rubin, A. S., Nascimento, D. Z., Sánchez-Valdeón, L., et al. (2015)
Pirfenidon plus Nintedanib bei idiopathischer pulmonaler Fibrose
Drakopanagiotakis, F. (2016) · Kompass Pneumologie · doi:10.1159/000448780
Kawano-Dourado, L. B., Zampieri, F. G., Cavalcanti, A. B., Damiani, L. P., & Kairalla, R. A. (2016) · European Respiratory Journal · doi:10.1183/13993003.01283-2016
Progressive Interstitial Lung Disease Nonresponse to Cyclophosphamide
Silver, K., Highland, K. B., & Silver, R. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_55
Die idiopathische Lungenfibrose Idiopathic Pulmonary Fibrosis
Prasse, A., Pneumologie, A., Item, F., et al. (2015)
Mission CPLF 2016 : les pneumopathies interstitielles à l’honneur !
Sanchez, O. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30086-6
Acute exacerbations of interstitial lung disease
Veltkamp, M., & Grutters, J. C. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10001816
Pneumopathies interstitielles diffuses
Wémeau-Stervinou, L. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(15)30078-1
Management of Interstitial Lung Diseases in Argentina: a Survey to Pulmonologists
Varela, B. E., Tabaj, G. C., Quadrelli, S., et al. (2015)
Bouvry, D., & Jouneau, S. (2015) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(15)30063-x
Idiopathic pulmonary fibrosis - or what new in idiopathic interstitial pneumonia
Doubková, M. (2016) · Interní medicína pro praxi · doi:10.36290/int.2016.015
Lung Cancer Complicated with Interstitial Lung Diseases
Minegishi, Y. (2017) · Springer eBooks · doi:10.1007/978-981-10-2002-5_15
Pirfenidon—Skuteczny lek w leczeniu samoistnego włóknienia płuc
Piotrowski, W. J. (2016) · Advances in respiratory medicine · doi:10.5603/arm.45560
Raghu, G., Rochwerg, B. N., Zhang, Y., Cuello‐García, C. A., Azuma, A., Behr, J., Brożek, J., Collard, H. R., Cunningham, W., Homma, S. A., et al. (2017) · Advances in respiratory medicine · doi:10.5603/arm.50373
Current pharmacotherapy of idiopathic pulmonary fibrosis
Vašáková, M. (2016) · Klinická farmakologie a farmacie · doi:10.36290/far.2016.006
Vicary, G. W. (2016) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2589
Wu, C., Lin, H., Zhang, G., & Zhang, X. (2017) · Rheumatology Current Research · doi:10.4172/2161-1149.1000214
[Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy]
Belisari, A., Bettoni, D., Cortesi, P. A., D’Angiolella, L. S., Mantovani, L. G., Sopo, G. M., & Nonis, M. (2017) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v18i1s.1300
Collard, H. R. (2017) · CHEST Journal · doi:10.1016/j.chest.2016.11.060
Respiratory Failure in a Patient with Idiopathic Pulmonary Fibrosis
Hadley, R. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-43341-7_30 · Cited by 2
Current concepts of idiopathic pulmonary fibrosis: focus on biomarkers
Anaev, E. K. (2017) · PULMONOLOGIYA · doi:10.18093/0869-0189-2017-27-1-56-64 · Cited by 2
III. New Treatment of Idiopathic Pulmonary Fibrosis
Kashiwada, T., & Azuma, A. (2016) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.105.970
“An Ounce of Prevention.. ”: Will This Be the Future for Idiopathic Pulmonary Fibrosis?
Lee, J. S. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1116ed
Un estudio de fase 3 de pirfenidona en pacientes con fibrosis pulmonar idiopática
Matiz, C. E., & Peña, A. P. (2016) · Revista Colombiana de Neumología · doi:10.30789/rcneumologia.v26.n4.2014.4
Antifibrosetherapie mit Überlebensvorteil
Wedekind, S. (2015) · Pneumo News · doi:10.1007/s15033-015-0207-7
Acetylcysteine in IPF: the knockout blow?
Norris, L. (2016)
Weniger Hospitalisierung aus respiratorischen Gründen bei IPF mit Pirfenidon
Markart, P., & Günther, A. (2017) · Pneumo News · doi:10.1007/s15033-017-0723-8
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.